Pharmatech, Inc., a Research Management Organization (RMO), has contracted with five leading pharmaceutical companies to provide research and site management services for their clinical trials using the Just-in-Time (JIT) enrollment strategy.
Pharmatech, Inc. Contracts for Five New Just-in-Time Clinical Trials
New JIT Enrollment Program Speeds Oncology Patient Accrual
DENVER, July 24, 2008 /PRNewswire via COMTEX/ -- Pharmatech, Inc., a Research Management Organization (RMO), has contracted with five leading pharmaceutical companies to provide research and site management services for their clinical trials using the Just-in-Time (JIT) enrollment strategy. The new trials include the following disease indications: follicular Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, Metastatic Sarcoma, Chronic Myelogenous Leukemia, and Non-Small Cell Lung Cancer (NSCLC).
Pharmatech will manage the trials using its innovative JIT approach. This streamlined approach was created to increase enrollment in oncology clinical trials. This patient first initiative allows for identification of cancer patients through basic standard of care procedures, so the site opens only if the patient qualifies for the study. Patient enrollment increases because a protocol is rolled out to a large number of qualified Research Network sites with minimal expense of time and capital for both the sites and sponsors.
The new oncology clinical trials are targeted to achieve enrollment of over 500 cancer patients with the participation of approximately 165 Pharmatech Research Network sites. Matthew Wiener, Pharmatech CEO, states that "The recent activity in new business has been a true testament to the acceptance of the Just-In-Time enrollment strategy. Study sponsors and sites have praised the new enrollment methodology, as cancer patients are treated in a more efficient manner and sponsors see their trials completed in a shorter time frame."
About Pharmatech, Inc.:
Pharmatech, headquartered in Denver, Colorado, is a Research Management Organization (RMO) dedicated to the highest quality of clinical research. Pharmatech provides services of a Site Management Organization (SMO) and a Contract Research Organization (CRO) with a focus in oncology clinical trials. Through an organized research network, the Company focuses on the development and utilization of therapeutic products among sponsors, investigators, and patients. For more information about Pharmatech, please visit http://www.pharmatech.com.
SOURCE Pharmatech, Inc.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.